ANAVEX NY TRÅD!! FEBRUAR 2022 POSITIV AVATAR FASE 3!
-
Du kom mig i forkøbet der Solsen.
Meget fine data må man sige!
Dr. Jaime Kulisevsky, MD, PhD, Principal Investigator of the trial, commented, "PDD is a debilitating disorder with significant co-morbidities and there has not been a mechanistically novel medication approved for PDD in over 20 years. Hence, new therapies are urgently needed to alleviate this suffering and disability. I am impressed with the robust improvement of the MDS-UPDRS across all sub-score parts I-IV coupled with the biomarker correlated outcome measures and I support the implementation of the ANAVEX
2-73 Phase 3 studies in Parkinson's disease and Parkinson's disease dementia, respectively." -
Anavex Overbevisende data i Parkinson!!
Præsentation af yderligere analyserede resultater fra PD fase 2 forsøget på:
2022 International Conference on Alzheimer's & Parkinson's Diseases and related neurological disorders, taking place in Barcelona, Spain, and virtually on March 15-20, 2022.Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference
All MDS-UPDRS Part I, II, III, IV sub-scores improved, including substantial majority of individual items between 71% and 92% SIGMAR1 mRNA expression significantly increased in ANAVEX®2-73-treated patients vs placebo (p=0.035) and was significantly associated with improvements of MDS-UPDRS scores and cognitive efficacy endpoints CDR system NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company
Yahoo Finance (finance.yahoo.com)
All MDS-UPDRS Part I, II, III, IV sub-scores improved, including substantial majority of individual items between 71% and 92%
SIGMAR1 mRNA expression significantly increased in ANAVEX
2-73-treated patients vs placebo (p=0.035) over the course of treatment and was significantly associated with improvements of MDS-UPDRS scores and cognitive efficacy endpoints CDR system.Dr. Jaime Kulisevsky, MD, PhD, Principal Investigator of the trial, commented, "PDD is a debilitating disorder with significant co-morbidities and there has not been a mechanistically novel medication approved for PDD in over 20 years. Hence, new therapies are urgently needed to alleviate this suffering and disability. I am impressed with the robust improvement of the MDS-UPDRS across all sub-score parts I-IV coupled with the biomarker correlated outcome measures and I support the implementation of the ANAVEX
2-73 Phase 3 studies in Parkinson's disease and Parkinson's disease dementia, respectively."Stor dosisafhængig effekt og med meget lille usikkerhed p=0,035!
Patienter forbedrede endda deres motorik!!
At de også blev mindre demente med den højeste dosis på 50 mg, vidste vi jo i forvejen, men ikke at de også forbedrede deres motorik - og igen uden bivirkninger!
Nu må markedet da se at vågne op!!! -
Anavex Oversigt præsentation Parkinson
https://stocktwits.com/symbol/AVXL
AVXL: Anavex Life Sciences Corp Latest Stock Price, Analysis, News and Trading Ideas
Get real-time Anavex Life Sciences Corp (AVXL) stock price, news, financials, community insights, and trading ideas. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits.
Stocktwits (stocktwits.com)
-
Anavex ... Eisai dropper samarbejdet med biogen på Aduhelm.
Anavex Life Sciences Corp (AVXL): From the Benzinga wire today: Biogen,...
powerwalker: From the Benzinga wire today: Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact 8:01 am, March 15, 2022 Portfolios: First Watchlist...
InvestorsHub (investorshub.advfn.com)
Det ville være en interessant partner til Anavex. Der er også nogle personrelationer, der kunne være adgang for et samarbejde.
Mener også de er med i "konsortiet"
Læser at Anavex arbejder på at give adgang til Blarcamesine for patienter flere steder - interessant hvad der kan ligge i det.
Data burde være gode nok til en godkendelse, men det plejer ikke at være nemt selv om det ville være oplagt.
10% på kursen er latterlig henset til potentialet endnu en gang er synliggjort.
-
Fantastisk post fra Veliger som mest poster på Stock Twist:
Veliger
Tuesday, March 15, 2022 8:15:06 PM
Re: Bourbon_on_my_cornflakes post# 354211
Post# of 354315
I'm impatient too. In the past I've shared my analysis of what the fair value and full potential may be here...and full potential is in the hundreds per share. I want to realize it now. I also know I'd be a lot more patient today if the whole bio sector had been flat the past 3-4 months instead of down by nearly 50%, and Anavex was still in the 20's. Unfortunately, that has not panned out.I've been a holder since 2015, and I'm employed in this sector. I can tell you that at an average burn rate of $2.3M a month, while advancing multiple, late stage trials with > $10B/annual revenue potential....there's not much better in terms of time/dollar value out there. There are CEOs that take home more than the Anavex annual burn per year. Yes,, it could be faster if we partnered for peanuts or had diluted the stock to something > 100M outstanding shares. I'm not going to play Monday morning cornerback on these decision, other than to point out that Chris has in the neighborhood of 6M options, and I trust his goal is to maximize the potential here. That said, when he makes statements about shareholder value he's talking about several years...not days, weeks or months. Like you, I still want to see us move faster, buy I accept where we are and that last patient enrolled in the Alzheimer's study is just finishing up week 40 of 48 this week.
I expect we have another 6 months of waiting before the real deal....a RETT NDA filed, 48-week PDD OLE data (building off the good news today), and Alzheimer's into Sept/Oct. I honestly think the NDA being filed (our first of many) will create a very large adjustment in fair value, as it implies Pre-NDA dialogue has led to the path to file and brings legitimacy (whether FDA, UK, Canada, TGA...) which I feel is lacking today. That NDA filing could be this Summer. Obviously an approval means so much more...and that first approval anywhere will force the market to drastically recalculate the fair value, which today is off by at least 4x. GLTA.
Anavex Life Sciences Corp (AVXL): I’m impatient too. In the past I’ve shar...
Veliger: I’m impatient too. In the past I’ve shared my analysis of what the fair value and full potential may be here…and full potential is in the hundreds per...
InvestorsHub (investorshub.advfn.com)
-
H.C. Wainwright Thinks Anavex Life Sciences' Stock is Going to Recover:
0 star analyst H.C. Wainwright's Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences (AVXL - Research Report) today and set a price target of $42.00. The company's shares closed last Tuesday at $10.65, close to its 52-week low of $9.28.
Ja ja hellere ha en 0 stjernet positiv analyst end ingen.
Interessant at han også har et kursmaal på over 40 ligesom Veliger i min forrige post, men okay Veliger mener nu og ikke om et år.
-
Anavex ... jeg kunne ikke loade mine egne notater fra Needham. Men her et par gode referater.
Anavex Life Sciences Corp (AVXL): My notes on Misslings CC this morning:...
RedShoulder: My notes on Misslings CC this morning: Rett Excellent in 2nd half of year. He was grilled pretty good on the change in end points for Rett. M...
InvestorsHub (investorshub.advfn.com)
Anavex Life Sciences Corp (AVXL): Peter, thanks again for you outstanding...
RedShoulder: Peter, thanks again for you outstanding analysis: Conclusions The improvents in all four parts of the UPDRS are consistent across all measures a...
InvestorsHub (investorshub.advfn.com)
Sidstnævnte med en analyse fra Peter Karol.
Jeg kan nævne Eisai som en mulig partner allerede nu fra Asien til AD, idet der sikkert skal nye forsøg til i asiater, idet adiater kan respondere anderledes en europæer og amerikanere.
God webcast med gode spørgsmål.
-
Anavex ... en tråd mere, idet Missling nævnte at der var flere sygdomme Blarcamesine var aktiv i:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168223924 -
Anavex Parkinson News Today!
PDD Patients Given Anavex 2-73 at High Dose Show Range of Benefits
Fik nu lejlighed til at høre Missling på Needham - har været lidt arbejdsramt.
Fine referarter længere oppe i tråden!
Anavex køre med fuld damp på alle cylinder!
Det er bare så vildt, hvilket potentiale hele platformen præsenterer.
Alle data har hidtil været meget overbevisende og uden sidestykke til nuværende mulig behandlingsform.
Anavex ved lige nøjagtig, hvad de har og hvor de skal hen.
Tingene tager tid, med RETT godkendelse er meget realistisk indenfor en kortere tidshorisont - afspejles af, at Anavex er ved at opbygge en salgsorganisation.
Partnerskaber sandsynligvis i Japan, kan komme hvornår det skal være - Takeda (konsortium) eller Eisia med tidligere Anavex konsulent Harald Hampel, som udviklingsleder af nye CNS forsøg for netop Eisai.
Dette i sig selv ville skubbe Anavex op i en anden liga og give en blåstempling af casen.Der er nu mange potentielle nyheder løbende resten af 2022 - med kronen på værket i form af Alzheimer fase 2/3 data, som Missling ikke var forsinket og ville komme i slutningen af 2022.
Holder eller øger og læner mig tilbage og lader tingene komme når de kommer.
Torpedoerne er skudt af - nu venter vi bare på, hvornår og ikke hvis de når målet! -
Anavex ... Endelig ser det ud til at kursen retter sig efter en urimelig nedkøling efter de gode Avatar resultater.
Det er USA biotech og man skal ikke nødvendigvis forstå kursudviklingen. Big money styrer langt hen ad vejen.
Vi kan håbe, at kursen glider forbi 13-13,5 for så er der åbnet op for yderligere 4-6 point, tror jeg.
Jeg har nævnt eksemplet CLDX før. Uden varsel eller nyheder fløj kursen op fra $2 til $50.
Mon vi kommer op i en rimelig værdisætning nu - eller må vi afvente approval og salgsindtægter ?
-
Ja det var en fin uge for os Anavex investorer, vores papir penge blev ca 20% forøget hvilket er psykologisk godt.
Det var også voldsomt volumen på, over 3 mill i fredags, hvilket også er meget fint, der er interesse i firmaet.
Hvis man kigger på XBI index kan man se at vi har fuldt det meget nøje men dog med doblet stigning men kurven ligner AVXL kurven meget for 5 dage. Bio Tech er generelt banket helt ned i kul kælderen, måske bunden var nået og folk investerer penge i Bio Tech igen?
Kursen på AVXL burde værre min 40 med den pipe-line og de kan ikke blive ved med at ignorere Anavex, jeg er optimistisk at det store volumen er de tunge drenge som køber ind, de er jo ikke dumme (men grådige).
-
Anavex Hvad er der sket med søgefunktionen??
Kan ikke finde egen aktivitet mm. -
Anavex Positiv Seeking Alpha artikel.
Blarcamesine is one of the very best drug candidates for the treatment of Alzheimer's disease.
The current timeline is for Anavex to release phase 3 clinical trial results for Alzheimer's disease during the latter part of this year, but this timeline could be pushed out into the early part of next year. Most investors in the company are probably used to these delays from previous Anavex trials (which also include Rett syndrome and Parkinson's Disease Dementia). More important is if the results remain positive, will the FDA approve a drug based on a phase 3 clinical trial with no U.S. sites? I suppose that it depends on how good the results are, but if the results match those from the open label trials, it is difficult to conceive that the FDA would not at least grant accelerated approval to blarcamesine. Anavex remains one of the very best investments in the Alzheimer's field.
The following article attempts to explain some of the mechanisms of action that may account for these varied results and why Anavex's blarcamesine may potentially provide a successful treatment for Alzheimer's disease.
-
Anavex Oplever også at flere funktioner ikke virker mere eller som de plejer?
Min historik og søgefunktionen, som plejer at ligge oppe i højre hjørne under login mangler.
På min Ipad er feltet der dog stadig, men virker ikke?
Når jeg er ved at skrive et indlæg og f.eks. vil hente et link, så forsvinder den tekst jeg allerede har skrevet?
Har I problemer på PI Helge eller er I under ombygning? -
Der er en fejl i linket. Der mangler et "/" efter .com. Et eksempel fra eneste mail..
-
Vi knokler løs næste fra tidlig morgen til sen aften. Det er en stor men meget nødvendig opgave, vi har sat os selv på med at udskifte kodning og i biblioteker i den gamle platform fra 2009. Meld endelig bugs ind på [email protected]
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind